No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HIMS Hims & Hers Health
- 19.420
- -0.950-4.66%
Close Jul 19 16:00 ET
- 19.482
- +0.062+0.32%
Post 19:55 ET
4.17BMarket Cap-1942000P/E (TTM)
21.115High19.040Low15.01MVolume20.730Open20.370Pre Close298.55MTurnover8.12%Turnover RatioLossP/E (Static)214.79MShares25.74052wk High12.11P/B3.59BFloat Cap5.65052wk Low--Dividend TTM184.80MShs Float25.740Historical High--Div YieldTTM10.19%Amplitude2.720Historical Low19.886Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Hims & Hers Health Shares Are Trading Lower Following a Report Suggesting That the Company Is Voluntarily Cooperating With a FTC Inquiry
Hims & Hers Says 'Voluntarily Cooperating' With FTC Inquiry
Hims & Hers Says 'Voluntarily Cooperating' With FTC
Truist Securities Adjusts Price Target on Hims & Hers Health to $23 From $13, Maintains Hold Rating
Hims & Hers Health (HIMS) has an average outperform rating and price target range of $13 to $26, according to analysts polled by Capital IQ.Price: 22.00, Change: +0.01, Percent Change: +0.05
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Announces Target Price $23
Truist Financial analyst Jailendra Singh maintains $Hims & Hers Health(HIMS.US)$ with a hold rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate of 37.0
Express News | Hims & Hers Health Inc : Truist Securities Raises Target Price to $23 From $13
Press Release: Hims & Hers to Announce Second Quarter 2024 Financial Results on August 5, 2024
Hims & Hers to Announce Second Quarter 2024 Financial Results on August 5, 2024 SAN FRANCISCO--(BUSINESS WIRE)--July 15, 2024-- Hims & Hers Health, Inc. ("Hims & Hers") (NYSE: HIMS), the leading
Comments
Jim Cramer shared his perspective on Hims & Hers Health, highlighting its recent performance and potential. He suggested that while buying after its pullback to $20 from recent highs around $25 might be justified, caution is advised. Cramer noted the company's strength in telehealth services, particularly in areas like sexual health and mental health, which have seen robust growth.
He emphasized that while Hims & Hers has benefited from offering compounded ...
He emphasized that while Hims & Hers has benefited from offering compounded ...
From YouTube
7
Today grabbing
$Dave Inc(DAVE.US$
PT $41+ SL $27
$Desktop Metal(DM.US$
LT PT: $17+
$Hims & Hers Health(HIMS.US$
LT PT: $39.27+
$Intel(INTC.US$
PT: $50 SL: $25
Medium duration, 14-30 days min.
$Dave Inc(DAVE.US$
PT $41+ SL $27
$Desktop Metal(DM.US$
LT PT: $17+
$Hims & Hers Health(HIMS.US$
LT PT: $39.27+
$Intel(INTC.US$
PT: $50 SL: $25
Medium duration, 14-30 days min.
3
1. $Tesla(TSLA.US$ -- Often assessed by traditional auto industry metrics, Tesla's Full Self-Driving technology is overlooked, which shifts the focus from selling cars to providing autonomous ride services.
2. $SoFi Technologies(SOFI.US$ -- Regarded as just another fintech company, SoFi distinguishes itself with a unified financial platform that spans loan refinancing, investment services, and per...
2. $SoFi Technologies(SOFI.US$ -- Regarded as just another fintech company, SoFi distinguishes itself with a unified financial platform that spans loan refinancing, investment services, and per...
11
3
1. $Palantir(PLTR.US$
It is referred as the “Messi of AI”.
This is well deserved as customers are flocking to its AIP.
It allows companies to integrate their data and create customized LLMs for their operations.
This translated to a 40% year-over-year increase in U.S. commercial sales to $150 million and 27% worldwide commercial sales growth to $299 million.
Annual revenue is set to grow at 30% CAGR in the next 5 years.
2. $NVIDIA(NVDA.US$
...
It is referred as the “Messi of AI”.
This is well deserved as customers are flocking to its AIP.
It allows companies to integrate their data and create customized LLMs for their operations.
This translated to a 40% year-over-year increase in U.S. commercial sales to $150 million and 27% worldwide commercial sales growth to $299 million.
Annual revenue is set to grow at 30% CAGR in the next 5 years.
2. $NVIDIA(NVDA.US$
...
+1
22
1
$Hims & Hers Health(HIMS.US$ Jesus we get it guys you sold some fake fat pills relax people want skinny every thing diet is bad for you 😂
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg